Codexis, Inc. Common Stock CDXS
i
Market dataready · fetched 2026-11-06T22:25:21.813Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T22:08:43.578141268Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-06T22:25:20.075283+00:00
Codexis, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 1.02 | 639.5% | 48.8% | |||
| 30Δ | 1.09 | 589.8% | 43.4% | |||
| 35Δ | 6.93 | 800.0% | 563.9% | 1.16 | 540.1% | 38.0% |
| 40Δ | 5.65 | 800.0% | 448.2% | 1.24 | 490.5% | 32.6% |
| 45Δ | 1.31 | 440.8% | 27.2% | |||
| 50Δ | 1.39 | 391.1% | 21.9% | |||
| 55Δ | 2.34 | 702.4% | 145.8% | 1.46 | 341.4% | 16.5% |
| 60Δ | 2.18 | 748.8% | 137.0% | 1.59 | 321.8% | 12.8% |
| 65Δ | 1.79 | 335.6% | 11.0% | |||
| 70Δ | 1.99 | 349.4% | 9.2% | |||
| 75Δ | 2.14 | 333.1% | 7.2% | |||
| 80Δ | 2.28 | 315.7% | 5.3% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.02
- IV
- 639.5%
- B/E move
- 48.8%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.09
- IV
- 589.8%
- B/E move
- 43.4%
35Δ
- Pseudo strike
- 6.93
- IV
- 800.0%
- B/E move
- 563.9%
- Pseudo strike
- 1.16
- IV
- 540.1%
- B/E move
- 38.0%
40Δ
- Pseudo strike
- 5.65
- IV
- 800.0%
- B/E move
- 448.2%
- Pseudo strike
- 1.24
- IV
- 490.5%
- B/E move
- 32.6%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.31
- IV
- 440.8%
- B/E move
- 27.2%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.39
- IV
- 391.1%
- B/E move
- 21.9%
55Δ
- Pseudo strike
- 2.34
- IV
- 702.4%
- B/E move
- 145.8%
- Pseudo strike
- 1.46
- IV
- 341.4%
- B/E move
- 16.5%
60Δ
- Pseudo strike
- 2.18
- IV
- 748.8%
- B/E move
- 137.0%
- Pseudo strike
- 1.59
- IV
- 321.8%
- B/E move
- 12.8%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.79
- IV
- 335.6%
- B/E move
- 11.0%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.99
- IV
- 349.4%
- B/E move
- 9.2%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.14
- IV
- 333.1%
- B/E move
- 7.2%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.28
- IV
- 315.7%
- B/E move
- 5.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 213.46% | |
| 269.78% | |
| 231.42% | |
| 235.33% | |
| 242.52% | |
| 239.03% | |
| 259.17% | |
| 279.96% | |
| 274.82% | |
| 309.32% |
Biotechnology
CELC
Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. The company is headquartered in…
More →CELU
Celularity Inc. is a pioneering biotechnology company focused on regenerative medicine through its innovative cellular products derived from the placenta. The company is advancing…
More →CGEM
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United…
More →CGON
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070, an oncolytic virus…
More →CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in…
More →CING
Description unavailable
More →